Leyden Laboratories B.V.: Leyden Labs' Intranasal PanFlu Antibody Enters the Clinic

Leyden Laboratories B.V., (the "Company" or "Leyden Labs") announced today the dosing of the first Phase 1 healthy volunteer cohort with a nasal spray containing PanFlu candidate CR9114. CR9114 is

Related Keywords

Olivia Durr ,Elizabeth Goodwin ,Jaap Goudsmit ,Leyden Lab ,Company Or Leyden Labs ,Janssen Pharmaceuticals Inc ,Company Phase ,Janssen Pharmaceutical Companies Of Johnson ,Leyden Labs ,Chief Scientific ,Koenraad Wiedhaup ,Chief Executive Officer ,Janssen Pharmaceuticals ,Janssen Pharmaceutical Companies ,Johnson ,Leyden ,Laboratories ,Labs ,Intranasal ,Panflu ,Ntibody ,Centers ,Clinic ,